In patients with lung cancer, different methods have been used successfully to detect EGFR mutations from ctDNA, and studies have demonstrated that this approach was valuable for diagnosis, predicting treatment response, and monitoring acquired therapy resistance [11,12]. The gene discussed is EGFR; the disease is lung cancer.